Goel Gaurav, Sun Weijing
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, 5150 Centre Avenue, Fifth Floor, Pittsburgh, PA, 15232, USA.
J Hematol Oncol. 2015 May 3;8:44. doi: 10.1186/s13045-015-0141-5.
Despite a few breakthroughs in therapy for advanced disease in the recent years, pancreatic ductal adenocarcinoma continues to remain one of the most challenging human malignancies to treat. The overall prognosis for the majority of patients with pancreatic cancer is rather dismal, and therefore, more effective treatment options are being desperately sought. The practical goals of management are to improve the cure rates for patients with resectable disease, achieve a higher conversion rate of locally advanced tumor into potentially resectable disease, and finally, prolong the overall survival for those who develop metastatic disease. Our understanding of the complex genetic alterations, the implicated molecular pathways, and the role of desmoplastic stroma in pancreatic cancer tumorigenesis has increased several folds in the recent years. This has facilitated the development of novel therapeutic strategies against pancreatic cancer, some of which are currently under evaluation in ongoing preclinical and clinical studies. This review will summarize the existing treatment approaches for this devastating disease and also discuss the promising therapeutic approaches that are currently in different stages of clinical development.
尽管近年来晚期疾病的治疗取得了一些突破,但胰腺导管腺癌仍然是最难治疗的人类恶性肿瘤之一。大多数胰腺癌患者的总体预后相当严峻,因此,人们迫切寻求更有效的治疗选择。治疗的实际目标是提高可切除疾病患者的治愈率,提高局部晚期肿瘤转化为潜在可切除疾病的转化率,最后,延长发生转移性疾病患者的总生存期。近年来,我们对胰腺癌发生过程中复杂的基因改变、相关分子途径以及促纤维增生性基质的作用的了解增加了数倍。这促进了针对胰腺癌的新型治疗策略的开发,其中一些目前正在正在进行的临床前和临床研究中进行评估。本综述将总结针对这种毁灭性疾病现有的治疗方法,并讨论目前处于不同临床开发阶段的有前景的治疗方法。